DHTRF (DRI Healthcare Trust) ROC (Joel Greenblatt) %: % (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHTRF DRI Healthcare Trust DHTRF
33 GF Score
Price $12.70
GF Value $13.35
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is DRI Healthcare Trust ROC (Joel Greenblatt) %?

DRI Healthcare Trust DHTRF 33 ROC (Joel Greenblatt) % is % as of Mar. 2026. GuruFocus rates DHTRF with a GF Score™ of 33/100 and a GF Value™ of $13.35 (Fairly Valued). The stock has 6 warning signs investors should review. Among 983 Drug Manufacturers companies, DRI Healthcare Trust ranks worse than 101729.3% on this metric.

ROC (Joel Greenblatt) % does not apply to banks and insurance companies.

DHTRF
33GF Score
DRI Healthcare Trust DHTRF
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a ROC (Joel Greenblatt) % of % mean?
DRI Healthcare Trust (DHTRF) has a ROC (Joel Greenblatt) % of % as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on DRI Healthcare Trust and its competitors. According to the industry distribution chart, DRI Healthcare Trust ranks #999999 out of 983 companies in the Drug Manufacturers industry.
Is DRI Healthcare Trust's ROC (Joel Greenblatt) % too high?
DRI Healthcare Trust's current ROC (Joel Greenblatt) % is %. Based on the distribution chart, DRI Healthcare Trust ranks #999999 out of 983 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, DRI Healthcare Trust has a GF Score™ of 33/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does DRI Healthcare Trust's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, DRI Healthcare Trust ranks #999999 out of 983 companies for ROC (Joel Greenblatt) %. This places DRI Healthcare Trust in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 11.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.46, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on DRI Healthcare Trust and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DRI Healthcare Trust's current ROC (Joel Greenblatt) % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DRI Healthcare Trust stock overvalued right now?
Based on GuruFocus' analysis, DRI Healthcare Trust (DHTRF) is currently considered Fairly Valued. The stock's GF Value™ is $13.35, compared to a current price of $12.70 — trading 4.9% below its estimated fair value. The current ROC (Joel Greenblatt) % is %. DRI Healthcare Trust's overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For DRI Healthcare Trust (DHTRF), the current ROC (Joel Greenblatt) % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DRI Healthcare Trust (DHTRF) Overvalued in 2026?

Based on GuruFocus' analysis, DRI Healthcare Trust stock appears to be undervalued. The current stock price of $12.70 is trading 4.9% below its estimated GF Value™ of $13.35. GuruFocus considers DRI Healthcare Trust to be Fairly Valued.

Key valuation signals for DHTRF:

  • ROC (Joel Greenblatt) %: %
  • GF Value™: $13.35 vs. price of $12.70 (4.9% below fair value)
  • GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the DHTRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DRI Healthcare Trust Business Description

Other Exchanges DHT.UN:CanadaDHT.U:Canada
Address 100 King Street West, 1 First Canadian Place, Suite 6200, Toronto, ON, CAN, M5X 1B8
DRI Healthcare Trust is an open-ended trust that purchases royalty entitlements on products that address unmet medical needs, providing its unitholders with top-line exposure to a portfolio of therapeutics. Its portfolio comprises several royalty streams on products that treat conditions in a number of therapeutic areas, including oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, as well as lysosomal storage disorders (LSD) and immunology. The Trust has concluded that it operates as one segment, focused on acquiring royalty assets. Geographically, it generates maximum royalty income from the sale of products underlying its royalty agreements in the United States, followed by other markets such as Japan, the European Union, and the rest of the world.
33GF Score

Get the complete analysis for DHTRF

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.70
Price
$13.35
GF Value